Setrusumab

Ultragenyx Pharmaceutical Inc., focusing on rare disease treatments, shows strong revenue growth and a promising pipeline, including a potential blockbuster for Osteogenesis Imperfecta. With a solid base business and significant market potential, its future hinges on clinical trial successes and regulatory approvals.

Mereo BioPharma announces CEO Dr. Denise Scots-Knight's presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company focuses on rare diseases with candidates like setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD, alongside oncology candidates. Partnerships and designations aim to advance treatments, with forward-looking statements highlighting potential risks and uncertainties.

Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will be webcast live and archived on the company's website. Mereo focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization.

STAT's biotech newsletter highlights key sector events, including Ultragenyx and Praxis's Phase 3 trials, Trump's FDA transition plan, Eli Lilly's lawsuit involvement over tirzepatide, and Biden's science and tech awards to CRISPR scientists and mRNA vaccine developers.